other material
confidence high
sentiment positive
materiality 0.55
Lyell Immunopharma to issue 625,000 shares upon achieving CAR T-cell clinical milestone
Lyell Immunopharma, Inc.
- Milestone for ImmPACT's next-gen CAR T-cell candidate achieved on June 20, 2025.
- 625,000 shares of common stock (post-1-for-20 reverse split) to be issued to ImmPACT securityholders.
- Shares issued in private placement exempt under Section 4(a)(2) of the Securities Act.
- Issuance is contingent consideration from the previously completed ImmPACT Bio merger.